Under the current US FDA regulations, manufacturers of any one of the above marketed TKIs who wants to gain an additional approval for treatment of RET-rearranged NSCLC will have to pay for the screening for thousands of NSCLC patients and the development of a RET-rearrangement CDx. Here, RET is linked to non-small cell lung carcinoma.